Details of Drug-Drug Interaction
| Drug General Information (ID: DDIMEC14QV) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Bivalirudin | Drug Info | Salicylic acid (sodium) | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antithrombotic Agents | Antiinflammatory Agents | |||||||
| Structure | |||||||||
| Mechanism of Bivalirudin-Salicylic acid (sodium) Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of bleeding Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Bivalirudin | Salicylic acid (sodium) | |||||||
| Mechanism |
Risk of bleeding Anticoagulant |
Risk of bleeding Antiplatelet effects |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Bleeding | ||||||||
| Factor Description | Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities. | ||||||||